Pro-Matrix Metalloproteinase-2 Transfection Increases Orthotopic Primary Growth and Experimental Metastasis of MDA-MB-231 Human Breast Cancer Cells in Nude Mice

The ability to activate pro-matrix metalloproteinase (pro-MMP)-2 via membrane type-MMP is a hallmark of human breast cancer cell lines that show increased invasiveness, suggesting that MMP-2 contributes to human breast cancer progression. To investigate this, we have stably transfected pro-MMP-2 into the human breast cancer cell line MDA-MB-231, which lacks MMP-2 expression but does express its cell surface activator, membrane type 1-MMP. Multiple clones were derived and shown to produce pro-MMP-2 and to activate it in response to concanavalin A. In vitro analysis showed that the pro-MMP-2-transfected clones exhibited an increased invasive potential in Boyden chamber and Matrigel outgrowth assays, compared with the parental cells or those transfected with vector only. When inoculated into the mammary fat pad of nude mice, each of the MMP-2-tranfected clones grew faster than each of the vector controls tested. After intracardiac inoculation into nude mice, pro-MMP-2-transfected clones showed a significant increase in the incidence of metastasis to brain, liver, bone, and kidney compared with the vector control clones but not lung. Increased tumor burden was seen in the primary site and in lung metastases, and a trend toward increased burden was seen in bone, however, no change was seen in brain, liver, or kidney. This data supports a role for MMP-2 in breast cancer progression, both in the growth of primary tumors and in their spread to distant organs. MMP-2 may be a useful target for breast cancer therapy when refinement of MMP inhibitors provides for MMP-specific agents.

[1]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[2]  R. Fridman,et al.  Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. , 2002, Journal of the National Cancer Institute.

[3]  C. Overall,et al.  Cellular Activation of MMP-2 (Gelatinase A) by MT2-MMP Occurs via a TIMP-2-independent Pathway* , 2001, The Journal of Biological Chemistry.

[4]  S. Sheen-Chen,et al.  Serum levels of matrix metalloproteinase 2 in patients with breast cancer. , 2001, Cancer letters.

[5]  Paul J. Williams,et al.  A Bone‐Seeking Clone Exhibits Different Biological Properties from the MDA‐MB‐231 Parental Human Breast Cancer Cells and a Brain‐Seeking Clone In Vivo and In Vitro , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  L. Devy,et al.  MT1‐MMP expression promotes tumor growth and angiogenesis through an up‐regulation of vascular endothelial growth factor expression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  A. Tumber,et al.  Human breast‐cancer cells stimulate the fusion, migration and resorptive activity of osteoclasts in bone explants , 2001, International journal of cancer.

[8]  Shiaw‐Der Yang,et al.  Suppression of proline‐directed protein kinase FA systemically inhibits the growth of human acute leukemia cells , 2001, International journal of cancer.

[9]  Jeffrey W. Smith,et al.  MT1-MMP Initiates Activation of pro-MMP-2 and Integrin αvβ3 Promotes Maturation of MMP-2 in Breast Carcinoma Cells , 2001 .

[10]  F. Cavalli,et al.  Identifying breast cancer patients at high risk for bone metastases. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Guise Molecular mechanisms of osteolytic bone metastases , 2000, Cancer.

[12]  A. Ferrando,et al.  Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. , 2000, Cancer research.

[13]  L. Coussens,et al.  Extrinsic regulators of epithelial tumor progression: metalloproteinases. , 2000, Current opinion in genetics & development.

[14]  M. Oursler,et al.  Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. , 1999, Cancer research.

[15]  C. López-Otín,et al.  Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. , 1999, Cancer research.

[16]  Charles D. McDermott,et al.  Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials , 1999, Annals of the New York Academy of Sciences.

[17]  L. Matrisian,et al.  The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. , 1998, Cancer research.

[18]  H. Shimada,et al.  Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. , 1998, Cancer research.

[19]  J. Foidart,et al.  In Vivo Evidence That the Stromelysin-3 Metalloproteinase Contributes in a Paracrine Manner to Epithelial Cell Malignancy , 1998, The Journal of cell biology.

[20]  S. Itohara,et al.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.

[21]  Y. Masuho,et al.  Identification of soluble type of membrane-type matrix metalloproteinase-3 formed by alternatively spliced mRNA. , 1997, Biochimica et biophysica acta.

[22]  J. Mohler,et al.  In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer , 1997, Clinical & Experimental Metastasis.

[23]  F. Hirahara,et al.  Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. , 1997, Human pathology.

[24]  C. Gilles,et al.  Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[25]  H. Chung,et al.  Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression , 1997, Breast Cancer Research and Treatment.

[26]  M. Polette,et al.  MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells , 1997, Clinical & Experimental Metastasis.

[27]  E. Thompson,et al.  Human breast cancer cell metastasis to long bone and soft organs of nude mice: a quantitative assay , 1997, Clinical & Experimental Metastasis.

[28]  G. Butler,et al.  Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. , 1997, European journal of biochemistry.

[29]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[30]  L. Matrisian,et al.  Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. , 1996, The American journal of pathology.

[31]  H. Sato,et al.  Complex Regulation of Membrane-type Matrix Metalloproteinase Expression and Matrix Metalloproteinase-2 Activation by Concanavalin a in Mda-mb-231 Human Breast Cancer Cells1 Activation of Which Has Been Associated with Metastatic Progression in Human Breast Cancer (hbc). Concanavalin a (con A) Has Be , 2022 .

[32]  P. Chambon,et al.  Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[34]  S. McLeskey,et al.  Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[35]  Jack P. Witty,et al.  Expression and localization of matrix‐degrading metalloproteinases during colorectal tumorigenesis , 1994, Molecular carcinogenesis.

[36]  Motoharu Seiki,et al.  A matrix metalloproteinase expressed on the surface of invasive tumour cells , 1994, Nature.

[37]  M. Lippman,et al.  Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. , 1993, Journal of the National Cancer Institute.

[38]  K. Tryggvason,et al.  Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. , 1993, The American journal of pathology.

[39]  T. Hurskainen,et al.  Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. , 1992, Cancer research.

[40]  Robert Clarke,et al.  Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines , 1992, Journal of cellular physiology.

[41]  J. Laborda,et al.  36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. , 1991, Nucleic acids research.

[42]  M. Cockett,et al.  Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). , 1991, The Biochemical journal.

[43]  J. Woessner,et al.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[45]  J. Price,et al.  Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. , 1990, Cancer research.

[46]  R. Baggs,et al.  A murine model of experimental metastasis to bone and bone marrow. , 1988, Cancer research.

[47]  J. Seltzer,et al.  H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. , 1988, The Journal of biological chemistry.

[48]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[49]  G. Martin,et al.  Basement membrane and the invasive activity of metastatic tumor cells. , 1986, Journal of the National Cancer Institute.

[50]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[51]  G. Laurie,et al.  Basement membrane complexes with biological activity. , 1986, Biochemistry.

[52]  M. Waltham,et al.  Correlation between extent of osteolytic damage and metastatic burden of human breast cancer metastasis in nude mice: Real-time PCR quantitation , 2004, Clinical & Experimental Metastasis.

[53]  Robin L. Anderson,et al.  MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits , 2004, Clinical & Experimental Metastasis.

[54]  P. Watson,et al.  A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. , 2001, European journal of cancer.

[55]  T. Yoneda Cellular and molecular basis of preferential metastasis of breast cancer to bone , 2000, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[56]  Y. Itoh,et al.  MEMBRANE-TYPE MATRIX METALLOPROTEINASES , 2017 .

[57]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases and metastasis , 1999, Cancer Chemotherapy and Pharmacology.

[58]  E. Kohn,et al.  The biochemistry of cancer dissemination. , 1997, Critical reviews in biochemistry and molecular biology.

[59]  P. Pavasant,et al.  Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays. , 1993, Breast cancer research and treatment.

[60]  N. Brünner,et al.  lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. , 1992, European journal of cancer.

[61]  L. Liotta,et al.  Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. , 1991, Cancer research.

[62]  F. Bergel Biochemistry of Cancer , 1963, Nature.